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Introduction 
Systemic sclerosis (SSc) is a rare connective tissue disease of unknown etiology associated 
with high morbidity and mortality [Rubio-Rivas 2014; Allanore 2015; Denton 2017]. The 
pathogenesis of SSc is characterized by systemic (multi-organ) immunological, vascular and 
fibrotic abnormalities [Allanore 2015]. SSc is highly heterogeneous in its manifestations and 
clinical course [Allanore 2015; Denton 2017]. Skin thickening, sclerosis and ulceration, 
particularly of the fingers, are common and can cause considerable disability [Hudson 2008; 
Matucci-Cerinic 2016], while the disease can also affect the pulmonary, cardiovascular, 
esophageal/gastrointestinal, musculoskeletal, and renal systems [Denton 2017]. Interstitial 
lung disease and pulmonary arterial hypertension are the most common causes of death 
related to SSc [Tyndall 2010]. In a meta-analysis of data from 13,529 patients published in 
2014, survival following diagnosis of SSc was estimated to be 74.9% at 5 years and 62.5% at 
10 years [Rubio-Rivas 2014].  
Systemic sclerosis-related interstitial lung disease (SSc-ILD) is characterized by progressive 
pulmonary fibrosis, decline in lung function, symptoms of cough and dyspnea, and 
impairment in health-related quality of life [Baron 2008; Khanna 2011; Jaeger 2016]. SSc-ILD 
shows similarities to idiopathic pulmonary fibrosis (IPF), a more common progressive 
fibrosing ILD of unknown cause, in its natural history, but tends to progress more slowly than 
IPF and to be associated with a non-specific interstitial pneumonia pattern on HRCT rather 
than usual interstitial pneumonia, as seen in IPF [Herzog 2014]. Acute deteriorations in lung 
function, known as acute exacerbations, occur in both SSc-ILD and IPF and are associated 
with very high morbidity and mortality [Tomiyama 2016; Collard 2016].  
Current treatment of SSc 
No drugs are approved for the treatment of SSc, but a multitude of drugs are used to treat 
specific manifestations of SSc and its associated comorbidities [Denton 2017]. 
Immunosuppressant therapy is most commonly used, in particular glucocorticoids, 
cyclophosphamide (CYC), mycophenolate mofetil (MMF) and methotrexate [Walker 2012; 
Siegert 2016; Adler 2017]. In Scleroderma Lung Study (SLS) I, conducted in 158 patients 
with SSc-ILD, treatment with CYC for 1 year provided a modest but significant benefit on 
forced vital capacity (FVC) per cent predicted versus placebo, as well as improvements in 
dyspnea and skin thickening [Tashkin 2006]. However, the use of CYC is limited due to its 
toxicity. In Scleroderma Lung Study II (SLS II), in which 142 patients with SSc-ILD received 
oral MMF for two years or oral CYC for 1 year followed by placebo for 1 year, improvements 
in FVC per cent predicted, dyspnea and skin thickness was observed at 2 years in both 
groups, with no significant difference between the groups, but with fewer treatment 
discontinuations due to adverse events in patients treated with MMF than CYC [Tashkin 
2016]. The latest treatment guidelines for SSc issued by the European League Against 
Rheumatism Collaborative Initiative (EULAR) and the EULAR Scleroderma Trials and 
Research Group (EUSTAR) recommend tailored CYC therapy for the treatment of SSc-ILD, 
particularly for patients with progressive disease [Kowal-Bielecka 2017]. These guidelines 
also recommend that autologous hematopoietic stem cell transplantation (HSCT) should be 
considered for selected patients with rapidly progressive SSc at risk of organ failure, with 
careful evaluation of the risk-benefit profile for individual patients. HSCT has shown 
considerable benefits in selected patients with SSc, but is associated with significant 
treatment-related mortality [Eyraud 2017].  
Pathogenesis of SSc and SSc-ILD 
The pathogenesis of SSc is complex and incompletely understood. The clinical 
manifestations of SSc are believed to result from distinct but interdependent processes: a) 
vascular damage involving microvascular endothelial cells leading to fibroproliferative 
vasculopathy and capillary rarefication, perivascular inflammation and autoimmune 
activation, b) innate and adaptive immune system abnormalities leading to production of 
autoantibodies, cell-mediated autoimmunity and the release of pro-fibrotic mediators and 
ultimately c) activation of fibroblasts to myofibroblasts, resulting in excessive deposition of 
extracellular matrix (ECM) in skin, lung, blood vessels and internal organs [Denton 2006; 
Pattanaik 2015].   
Damage to vascular endothelial cells, which may result from physical trauma, ischemia 
reperfusion injury, infectious agents, cytotoxic T cells, autoantibodies or oxidative stress, 
evokes the release of chemokines, endothelins, platelet-derived growth factor and vascular 
endothelial growth factor [Distler 2002; Distler 2004]. These alter endothelial permeability 
and promote the recruitment and proliferation of leukocytes. Under normal conditions, these 
factors and cells would orchestrate the healing process, stimulating tissue repair and scar 
resolution. However, in SSc, repeated vascular injury and a failure to resolve the 
inflammatory response and repair the endothelium evoke adaptive and innate immunologic 
mechanisms, including the accumulation of macrophages and neutrophils, which enhance 
the recruitment of lymphocytes to sites of injury. The role of endothelial apoptosis in the 
pathogenesis of SSc is not clear. Apoptosis of endothelial cells may contribute to tissue 
injury when they are engulfed by macrophages and immature dendritic cells, which then 
present cellular antigens to T cells [Albert 2001]. Apoptotic endothelial cells can also activate 
the complement and coagulant pathway, leading to vasculopathy [Tsuji 1994; Greeno 1996]. 
The involvement of monocytes/macrophages in the development and progression of SSc is 
also debated. Classically activated macrophages of the M1 type and alternatively activated 
macrophages of the M2 type belong to several subgroups stimulated by mediators like IFN, 
TNF, IL-4, IL-13, IL-10 and M-CSF. Both M1 and more prominently M2 signatures have been 
described in the blood, skin and lung of patients with SSc, but their relevance remains to be 
defined [Stifano 2016].  
Plasma cells secrete highly specific autoantibodies against host cell antigens and can 
exacerbate tissue injury. Endothelial-derived chemokines and growth factors recruit and 
activate mesenchymal progenitor cells and resident fibroblasts. Profibrotic factors secreted 
by activated T cells promote fibroblast activation and the synthesis and secretion of ECM. 
Differentiation of fibroblasts into contractile myofibroblasts expressing alpha smooth muscle 
actin amplifies the pathologic processes. Persistent production and deposition of ECM 
components, notably the fibrillar collagens type I and III, within connective tissues leads to 
fibrosis, tissue contraction and scarring. This inflammation phase is characterized by T-cell 
activation and the development of T-cells with predominantly type 2 T-helper-cell profibrotic 
cytokine profiles (IL-4, IL-5, IL-13). Other T-cell subsets and B cells are also present in 
lesions and exhibit intrinsic abnormalities in their phenotype and function. Inflammation is 
critical to the activation, recruitment and expansion of mesenchymal cell populations, 
including fibroblasts, pericytes and circulating progenitor cells, which contribute to the 
scarring process.   
SSc-ILD shows similarities to IPF in the pathophysiology of the underlying fibrotic cascade. 
While the initiating and amplifying events are described to be different in SSc-ILD and IPF 
[Herzog 2014], both culminate in fibroblast activation, migration, proliferation and 
myofibroblast accumulation with excessive ECM deposition; this represents a common final 
pathway of lung fibrosis [Bagnato 2015].    
Mechanism of action of nintedanib in SSc and SSc-ILD 
Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) that binds competitively to the 
adenosine triphosphate (ATP) binding pocket of kinases, blocking their downstream 
signalling [Wollin 2015]. Nintedanib targets the receptors platelet-derived growth factor 
receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, and VEGFR 1-3 
[Hilberg 2008; Wollin 2014]. In addition, nintedanib inhibits Flt-3 (Fms-like tyrosine-protein 
kinase), Lck (lymphocyte-specific tyrosine-protein kinase), Lyn (tyrosine-protein kinase lyn), 
Src (proto-oncogene tyrosine-protein kinase src) kinases [Hillberg 2008] and the colony-
stimulating factor 1 receptor (CSF1R) [Tandon 2017; Hilberg 2018]. Several of these kinase 
targets have been linked to pathogenic processes in lung fibrosis [Inoue 1996; Bonner 2004; 
Beyer 2013]. Recently, additional potential kinase targets were described for nintedanib 
[Hilberg 2018], but their relevance for its anti-fibrotic activity is unknown.  
Nintedanib was originally developed to be a treatment for non-small cell lung cancer by 
blocking neo-angiogenesis and with it, tumor growth. Pre-clinical pharmacodynamic 
exploration revealed that nintedanib attenuates the proliferation of three cell types 
contributing to angiogenesis: endothelial cells, pericytes, and smooth muscle cells [Hillberg 
2008]. Later, nintedanib was developed as a treatment for IPF, which shows several 
similarities in pathogenic pathways to cancer [Vancheri 2015]. Based on clinical trial data 
showing that nintedanib reduces the progression of IPF by slowing decline in lung function 
[Richeldi 2011; Richeldi 2014], nintedanib has been approved for the treatment of IPF in 
many countries worldwide.  
The mode of action of nintedanib in lung fibrosis has been characterized based on in vitro 
studies and in vivo models. Nintedanib inhibits the proliferation, migration and contraction of 
lung fibroblasts from patients with IPF [Wollin 2015], as well as attenuating the differentiation 
and migration of pro-fibrotic fibrocytes [Sato 2017] and the transformation of lung fibroblasts 
to myofibroblasts [Wollin 2014]. Recently, nintedanib was also shown to restore the elastic 
modulus of fibrotic matrices to reverse the myofibroblastic phenotype of pericytes [Sava 
2017]. Nintedanib has demonstrated anti-fibrotic and anti-inflammatory activity in animal 
models of lung fibrosis created using a variety of triggers [Wollin 2014; Wollin 2015; 
Ackermann 2017].  In these models, nintedanib attenuated the accumulation of lymphocytes 
in bronchoalveolar lavage fluid; reduced levels of interleukin-1β, the chemokine CXCL1/KC, 
and the tissue inhibitor of metalloproteinases-1; blocked expression of fibrosis-related marker 
genes such as TGFβ1 and procollagen 1; reduced histology scores of inflammation, 
granuloma formation and fibrosis in the lungs; reduced lung tissue density and the collagen 
content of lung tissue; and improved static lung compliance [Wollin 2014; Wollin 2015; 
Ackermann 2017]. In a mouse model of bleomycin-induced lung fibrosis, nintedanib also 
attenuated vascular proliferation, resulting in normalization of the distorted microvascular 
architecture [Ackermann 2017]. 
Recent in vivo investigations have revealed antifibrotic and anti-inflammatory activities of 
nintedanib in animal models of aspects of SSc. In bleomycin-induced skin fibrosis, graft 
versus host disease-induced skin fibrosis, tight skin (fibrillin1 transgenic), and Fra-2 mouse 
models of SSc, nintedanib reduced myofibroblast accumulation and ECM deposition in skin 
and lung, attenuated skin and lung fibrosis, and reduced dermal thickening [Huang 2016; 
Huang 2017]. In Fra-2 +/- transgenic mice, nintedanib also attenuated pulmonary vascular 
remodeling by reducing the number of vascular smooth muscle cells, pulmonary vascular 
wall thickness and occluded pulmonary vessels and by inhibiting microvascular endothelial 
cell apoptosis, and reduced the extent of fibrosis, perivascular inflammation and endothelial 
cells apoptosis in the heart [Huang 2017]. In in vitro studies, nintedanib has been shown to 
block the release of pro-fibrotic mediators from human peripheral blood monocytic cells and 
T cells [Wollin 2017] and reduce the M2 polarization of human macrophages incubated with 
macrophage colony-stimulating factor, interleukin IL-4 and IL-13 [Huang 2017; Tandon 
2017]. In experiments in dermal fibroblasts from patients with SSc, nintedanib inhibited 
fibroblast migration and proliferation, reduced the expression of ECM markers collagen 1a1, 
1a2, and fibronectin, and attenuated transformation of fibroblasts to myofibroblasts as 
detected by reductions in αSMA and stress fibers [Huang 2016]. An overview of the pre-
clinical exploration of nintedanib in dermal fibroblasts from patients with SSc and in in vivo 
models of SSc/SSc-ILD is presented in Tables 1 and 2. 
The comparable efficacy of nintedanib in animal models of lung fibrosis and SSc suggests 
that the effective dose may be comparable in patients with IPF and SSc. Nintedanib 
effectively inhibited fundamental processes of skin fibrosis (i.e., the proliferation and 
migration of dermal fibroblasts) at concentrations of 100 nM, which are close to the exposure 
levels achieved in humans (59 - 74 nmol/L) after steady state oral dosing of nintedanib 150 
mg twice daily in patients with IPF [Mross 2010; Eisen 2013].  
Clinical investigation of nintedanib in SSc-ILD 
The efficacy and safety of nintedanib in patients with SSc-ILD are being assessed in the 
randomized placebo-controlled SENSCIS trial (ClinicalTrials.gov NCT02597933; EudraCT 
2015-000392-28) [Distler 2017]. Over 520 patients aged ≥18 years with onset of SSc (first 
non-Raynaud symptom) ≤7 years before screening, ILD (≥10% fibrosis of the lungs on 
HRCT), FVC ≥40% predicted and diffusion capacity of the lung for carbon monoxide 30–89% 
predicted have been enrolled. Patients receiving low-dose prednisone and/or stable 
background therapy with MMF or methotrexate have been included in the trial, to reflect 
clinical practice. Patients have been randomized to receive nintedanib 150 mg twice daily or 
placebo. Randomized patients were stratified by the presence of anti-Scl-70/anti-
topoisomerase I antibody, which has been associated with accelerated progression of ILD 
[Assassi 2010]. The primary endpoint is the annual rate of decline in FVC (mL/year) 
assessed over 52 weeks. Key secondary endpoints are absolute changes from baseline in 
the modified Rodnan Skin Score (a measure of skin thickening in patients with SSc) and in 
the St George’s Respiratory Questionnaire total score (a measure of health-related quality of 
life) at week 52. The SENSCIS trial is due to be completed near the end of 2018.  
Conclusions  
There is a high unmet need for effective treatments for SSc-ILD. Nintedanib is an approved 
treatment for IPF, which shows clinical and mechanistic similarities to SSc-ILD. Nintedanib 
interferes at multiple critical steps in the pathobiology of SSc/SSc-ILD and has demonstrated 
anti-inflammatory and anti-fibrotic activities and attenuated vascular remodeling in several 
models of SSc/SSc-ILD, providing a strong rationale for its investigation as a treatment for 
SSc-ILD. The efficacy and safety of nintedanib in patients with SSc-ILD are currently being 
investigated in the Phase III SENSCIS® trial.  
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Tables and Figures 
Error! Reference source not found. Exploration of Nintedanib in Dermal Fibroblasts from 
Patients with SSc [Huang 2016] 
Model system/characteristics   Effects of nintedanib 
TGF- and PDGF-induced ECM 
components and markers of fibroblast to 
myofibroblast transformation 
Collagen 1a1, 1a2, fibronectin, αSMA 
mRNA  
 
Collagen, stress fibers and TGF 
signaling  
TGF- and PDGF-induced proliferation 
and migration of fibroblasts  
TGF- and PDGF-induced proliferation  
 
TGF- and PDGF-induced migration  
ECM, extracellular matrix; PDGF, platelet-derived growth factor; αSMA, alpha smooth muscle 
actin; TGF, transforming growth factor beta. 
 
  
Error! Reference source not found.Exploration of Nintedanib in Mouse Models of SSc 
/SSc-ILD [Huang 2016; Huang 2017]  
Model  system Model characteristics Treatment regimen Effects of nintedanib 
Bleomycin-induced 
skin fibrosis   
Skin damage-induced/ 
inflammation-induced 
fibrosis   
Preventive 
(weeks 0-3) 
and therapeutic 
(weeks 3-6) 
Skin:  
Myofibroblast count  
Dermal thickness  
Hydroxyproline  
Graft versus host 
disease-induced 
skin fibrosis   
Resembles aspects of 
early inflammatory stage 
of SSc 
Therapeutic 
(weeks 4-8) 
Skin:  
Myofibroblast count  
Dermal thickness  
Hydroxyproline  
Tight skin 
(fibrillin1 
transgenic)   
Resembles aspects of 
later stage of SSc with 
less inflammation, but 
early autoantibody 
production and massive 
fibrosis  
Therapeutic 
(weeks 5–10) 
Skin:  
Myofibroblast count  
Hypodermal thickness  
Hydroxyproline  
Fra-2 (AP-1 family 
transcription factor 
+/-)   
Resembles aspects of 
skin and lung fibrosis 
including microvascular 
disease and pulmonary 
hypertension with typical 
vascular lesions 
Therapeutic 
(weeks 9-16) 
Skin: 
Myofibroblasts count  
Dermal thickness  
Hydroxyproline  
MVEC apoptosis  
Capillary loss  
M2 macrophages  
 
Lung: 
Myofibroblast count  
ECM  
Vessel wall thickness  
Occluded vessels  
VSMC  
MVEC apoptosis  
 
Heart:  
Extent of fibrosis  
Perivascular inflammation  
Endothelial cells apoptosis  
ECM, extracellular matrix; VSMC; lung vascular smooth muscle cells; MVEC, dermal 
microvascular endothelial cells.   
Figure 1. Effects of Nintedanib on Pathogenic Mechanisms with Potential Relevance in 
SSc 
This figure depicts pathogenic mechanisms of SSc that have been shown to be targeted by 
nintedanib in experiments on human cells or in animal models resembling aspects of SSc 
and lung fibrosis.  
Nintedanib potently targets fibroblast growth factor receptors (FGFR), platelet-derived growth 
factor receptors (PDGFR), vascular endothelial growth factor receptor (VEGFR), lymphocyte-
specific tyrosine-protein kinase (Lck) and colony-stimulating factor 1 receptor (CSF1R). 
Nintedanib also exerts vascular effects, i.e. inhibits the proliferation of endothelial cells and 
pericytes. Nintedanib reduces the recruitment of lymphocytes to the lung. Nintedanib inhibits 
the differentiation and migration of fibrocytes and the migration, proliferation and contraction 
of fibroblasts. By reducing the number of fibroblasts and their transformation to 
myofibroblasts, the secretion of extracellular matrix (ECM) is reduced. Further, nintedanib 
blocks the differentiation of alternatively activated macrophages and the release of pro-
fibrotic mediators from T cells involved in the initiation of fibrosis. 
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